MX2019007797A - Antagonistas de integrinas. - Google Patents

Antagonistas de integrinas.

Info

Publication number
MX2019007797A
MX2019007797A MX2019007797A MX2019007797A MX2019007797A MX 2019007797 A MX2019007797 A MX 2019007797A MX 2019007797 A MX2019007797 A MX 2019007797A MX 2019007797 A MX2019007797 A MX 2019007797A MX 2019007797 A MX2019007797 A MX 2019007797A
Authority
MX
Mexico
Prior art keywords
pharmaceutical agents
integrins
compounds
integrin antagonists
avß8
Prior art date
Application number
MX2019007797A
Other languages
English (en)
Inventor
G Ruminski Peter
W Griggs David
Seiwert Scott
Original Assignee
Univ Saint Louis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Saint Louis filed Critical Univ Saint Louis
Publication of MX2019007797A publication Critical patent/MX2019007797A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente exposición proporciona agentes farmacéuticos, incluidos los de la fórmula: (I) en donde las variables se definen en el presente documento. También se proporcionan composiciones farmacéuticas, equipos y artículos de fabricación que comprenden dichos agentes farmacéuticos. También se proporcionan métodos de uso de los agentes farmacéuticos. Los compuestos pueden utilizarse para la inhibición o el antagonismo de las integrinas aVß1 y/o a5ß1. En algunas modalidades, los compuestos proporcionados en el presente documento muestran una actividad inhibitoria o antagonista reducida de las integrinas aVß3, aVß5, aVß6, aVß8 y/o aIIbß3.(ver fórmula I).
MX2019007797A 2016-12-29 2017-12-28 Antagonistas de integrinas. MX2019007797A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662440253P 2016-12-29 2016-12-29
US201762471882P 2017-03-15 2017-03-15
PCT/US2017/068801 WO2018132268A1 (en) 2016-12-29 2017-12-28 Integrin antagonists

Publications (1)

Publication Number Publication Date
MX2019007797A true MX2019007797A (es) 2019-10-21

Family

ID=62840040

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019007797A MX2019007797A (es) 2016-12-29 2017-12-28 Antagonistas de integrinas.

Country Status (14)

Country Link
US (1) US11306084B2 (es)
EP (1) EP3562826A4 (es)
JP (1) JP2020504120A (es)
KR (1) KR20190100232A (es)
CN (1) CN110177787A (es)
AU (1) AU2017393297A1 (es)
BR (1) BR112019012515A2 (es)
CA (1) CA3045491A1 (es)
CO (1) CO2019007023A2 (es)
IL (1) IL267686A (es)
MX (1) MX2019007797A (es)
PH (1) PH12019501514A1 (es)
RU (1) RU2019116820A (es)
WO (1) WO2018132268A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190100232A (ko) 2016-12-29 2019-08-28 세인트 루이스 유니버시티 인테그린 길항제
EP4147698A1 (en) 2017-02-28 2023-03-15 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
JP7092784B2 (ja) 2017-02-28 2022-06-28 モーフィック セラピューティック，インコーポレイテッド αｖβ６インテグリン阻害剤
JP2021535141A (ja) 2018-08-29 2021-12-16 モーフィック セラピューティック，インコーポレイテッド αｖβ６インテグリンの阻害

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1289983A2 (en) 2000-06-15 2003-03-12 Pharmacia Corporation Heteroarylalkanoic acids as integrin receptor antagonists
BR0317600A (pt) 2002-12-20 2005-11-29 Pharmacia Corp ácidos heteroarilalcanóicos como derivados de antagonistas de receptor de integrina
AU2003297408A1 (en) 2002-12-20 2004-07-22 Pharmacia Corporation Thiazole compounds as integrin receptor antagonists derivatives
WO2004058761A1 (en) * 2002-12-20 2004-07-15 Pharmacia Corporation Pyrazole compounds as integrin receptor antagonists derivatives
US8716226B2 (en) * 2012-07-18 2014-05-06 Saint Louis University 3,5 phenyl-substituted beta amino acid derivatives as integrin antagonists
AU2013292580B2 (en) * 2012-07-18 2017-07-20 Saint Louis University Beta amino acid derivatives as integrin antagonists
WO2015048819A1 (en) 2013-09-30 2015-04-02 The Regents Of The University Of California Anti-alphavbeta1 integrin compounds and methods
CA3042693A1 (en) 2016-11-08 2018-05-17 Bristol-Myers Squibb Company Pyrrole amides as .alpha.v integrin inhibitors
EA038164B1 (ru) 2016-11-08 2021-07-16 Бристол-Маерс Сквибб Компани 3-замещенные пропановые кислоты в качестве ингибиторов интегрина v
WO2018089358A1 (en) 2016-11-08 2018-05-17 Bristol-Myers Squibb Company Azole amides and amines as alpha v integrin inhibitors
CA3042714A1 (en) 2016-11-08 2018-05-17 Bristol-Myers Squibb Company Indazole derivatives as a .alpha.v integrin antagonists
WO2018089355A1 (en) 2016-11-08 2018-05-17 Bristol-Myers Squibb Company Cyclobutane- and azetidine-containing mono and spirocyclic compounds as alpha v integrin inhibitors
KR20190100232A (ko) 2016-12-29 2019-08-28 세인트 루이스 유니버시티 인테그린 길항제
EP4147698A1 (en) 2017-02-28 2023-03-15 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
KR20210043561A (ko) 2018-06-27 2021-04-21 플라이언트 테라퓨틱스, 인크. 비분지형 링커를 갖는 아미노산 화합물 및 사용 방법
WO2020009889A1 (en) 2018-07-03 2020-01-09 Saint Louis University ALPHAvBETA1 INTEGRIN ANTAGONISTS

Also Published As

Publication number Publication date
BR112019012515A2 (pt) 2019-11-19
JP2020504120A (ja) 2020-02-06
CN110177787A (zh) 2019-08-27
RU2019116820A (ru) 2021-01-29
PH12019501514A1 (en) 2020-09-14
WO2018132268A8 (en) 2019-06-20
CO2019007023A2 (es) 2019-07-31
EP3562826A4 (en) 2020-08-26
WO2018132268A1 (en) 2018-07-19
EP3562826A1 (en) 2019-11-06
US11306084B2 (en) 2022-04-19
US20190345155A1 (en) 2019-11-14
KR20190100232A (ko) 2019-08-28
CA3045491A1 (en) 2018-07-19
AU2017393297A1 (en) 2019-06-13
IL267686A (en) 2019-08-29

Similar Documents

Publication Publication Date Title
PH12019501514A1 (en) Integrin antagonists
PH12020551315A1 (en) Benzoxazepin oxazolidinone compounds and methods of use
NZ772349A (en) Sulfonylureas and related compounds and use of same
MX2019005306A (es) Compuestos mono y espirociclicos que continen ciclobutano y azetidina como inhibidores de la integrina alfa v.
PH12017502107A1 (en) Triazole agonists of the apj receptor
MY192059A (en) Heterocyclic amides as kinase inhibitors
SG10201908839QA (en) 2,4-dihydroxy-nicotinamides as apj agonists
WO2016023014A3 (en) Uses of salt-inducible kinase (sik) inhibitors
TR201911244T4 (tr) İmidazolonilkinolinler ve atm kinaz inhibitörleri olarak kullanımı.
EA033497B1 (ru) 1-(тиофенил или фенил)сульфонил-(пирролидин)-2-карбоксамидные производные и их применение в качестве антагонистов trpa1
MD20170070A2 (ro) Derivaţi de chinazolină utilizaţi în tratamentul HIV
MX2021014531A (es) Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos.
MX2018003554A (es) Benzamidas sustituidas con isoxazolina y analogos como insecticidas.
MX2016015565A (es) Ciertos inhibidores de la proteina quinasa.
PH12018501362A1 (en) Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists
PH12019500394A1 (en) Bicyclic nitrogenated heterocyclic compound
MX2022002976A (es) Inhibidores selectivos de jak1.
GEP20186910B (en) 1,2-substituted cyclopentanes as orexin receptor antagonists
PH12016502347A1 (en) 1 -(cyclopent-2-en-1 -yl)-3-(2-hydroxy-3-(arylsulfonyl)phenyl)urea derivatives as cxcr2 inhibitors
MX2018015872A (es) Derivados de benzodioxano y su uso farmaceutico.
MX2021001786A (es) Antagonistas de integrina.
PH12017501214A1 (en) Cgrp antagonist peptides
PL399012A1 (pl) Pochodna 1,2,4-triazolu-5-(3-chlorofenylo)-4-heptylo-2,4-dihydro-3H-1,2,4-triazolo-3-tion, sposób jej wytwarzania oraz jej zastosowanie medyczne